Trials / Withdrawn
WithdrawnNCT00518921
Capadenoson in Angina Pectoris
Phase IIa Efficacy and Safety Trial of Capadenoson in Patients With Chronic Stable Angina
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- 35 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a multi-center and multi-national,randomized, double blind, placebo-controlled, 28-day treatment study with BAY 68-4986 taken orally or a matching placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Capadenoson (BAY 68-4986) | 1mg Capadenoson, double dummy |
| DRUG | Capadenoson (BAY 68-4986) | 2mg Capadenoson, double dummy |
| DRUG | Capadenoson (BAY 68-4986) | 4mg Capadenoson, double dummy |
| DRUG | Placebo | Placebo, double dummy |
Timeline
- Start date
- 2008-03-01
- Completion
- 2008-11-01
- First posted
- 2007-08-21
- Last updated
- 2011-01-13
Locations
36 sites across 6 countries: Czechia, Hungary, Israel, Italy, Poland, Slovakia
Source: ClinicalTrials.gov record NCT00518921. Inclusion in this directory is not an endorsement.